Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Patients With Relapsed and Refractory Multiple Myeloma

NCT03312530 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03312530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03312530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Patients With Relapsed and Refractory Multiple Myeloma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Completed
Start date
November 13, 2017
Completion date
May 18, 2021
Enrollment
49 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma